AGREEAnalytical GREEnness metric approach and software
This consolidated filing outlines common allegations against Novo Nordisk and Eli Lilly, claiming the drug makers failed to adequately warn about severe gastrointestinal side effects such as gastroparesis, intestinal obstruction, and ischemic bowel
Patients should not overgeneralize this finding
There were no Gln group differences in any ROI even when focused on only the studies at 7T (seven studies), which had the greatest resolution to separate Glu from Gln
[1] [2] Common GLP-1 medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), while tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist
Gut 54, 242249